The Utah NeuroRobotics Lab was awarded a $300,000 contract from the company Biologic Input Output Systems (BIOS) to continue the lab's ongoing Investigational Device Exception Early Feasibility Study for the "LUKE Arm" neuroprosthesis. The lab is now actively recruiting one transradial amputee to enroll in the ongoing clinical trial. This individual will have Utah Slanted Electrode Arrays (USEAs) and intramuscular electromyographic recording leads (iEMGs) implanted into their residual arm nerves and muscles. This neural interface will then allow them to control a multiarticulate bionic arm simply with their thoughts, as well as receive a sense of touch coming back from the bionic arm. This upcoming patient will be the 9th patient in this clinical trial, and will receive the latest version of the technology, featuring new software that enhances dexterity and ease of use. Most importantly, this patient will be the first patient to take the device home and use it in a completely unsupervised manner. In the past, patients had to visit the lab to use the bionic arm under supervision of PhD-level engineers. Now, thanks to advancements made by the University of Utah and BIOS patients will be able to take home the device for use in their own activities of daily living.
This next phase of the project marks an exciting step towards the commercialization and real-world implementation of an advanced neuroprosthesis. This project also represents an ongoing academic-industry partnership between the University of Utah and BIOS. BIOS is a startup company associated with the University of Utah. In 2022, BIOS executed a software licensing agreement with the University of Utah for the technology behind the neuroprosthesis, which now serves as the core intellectual property for BIOS's flagship neuroprosthesis product. Dr. George, director of the Utah NeuroRobotics Lab, also serves as the Chief Scientist for BIOS. The USEAs used in this project are also manufactured by Blackrock Neurotech, another University of Utah associated company.